- Salarius Pharma ( NASDAQ: SLRX ) said on Monday it had added Mayo Clinic to its open-label Phase 1/2 trial with seclidemstat in Ewing’s sarcoma and FET-rearranged sarcomas.
- Mayo Clinic locations in Rochester, Minnesota, and Jacksonville, Florida are supporting trial enrollment, the company said.
- Seclidemstat targets a protein called LSD1 inhibitor that affects gene expression currently being studied in Phase 1/2 clinical studies for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progression.
- The company expects to report interim data from the trial in the second half of the year.
For further details see:
Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers